We are live on ! Find out more
IMPL

Impel Pharmaceuticals Inc. Common Stock
IMPL

Delisted

IMPL was delisted on the 15th of December, 2023.

Back to rankings

35 hedge funds and large institutions have $99.6M invested in Impel Pharmaceuticals Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 6 increasing their positions, 10 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 2 → 4 (+2)

35% more capital invested

Capital invested by funds: $73.9M → $99.6M (+$25.7M)

10% less funds holding

Funds holding: 39 → 35 (-4)

40% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 10

40% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 10

Holders
35
Holders Change
-4
Holders Change %
-10.26%
% of All Funds
0.56%
Holding in Top 10
4
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+100%
% of All Funds
0.06%
New
6
Increased
6
Reduced
10
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
JGC
J. Goldman & Co
New York
+$730K
2
Citadel Advisors
Citadel Advisors
Florida
+$133K
3
RJA
Raymond James & Associates
Florida
+$52.8K
4
Jane Street
Jane Street
New York
+$47.9K
5
MP
McDonald Partners
Ohio
+$42.6K

Top Sellers

Rank Fund Capital Flow
1
OM
Opaleye Management
Massachusetts
-$1.24M
2
DA
DCF Advisers
Connecticut
-$522K
3
BlackRock
BlackRock
New York
-$327K
4
Millennium Management
Millennium Management
New York
-$155K
5
BCM
Bridgeway Capital Management
Texas
-$128K
Name Holding Trade Value Shares
Change 		Change in
Stake
LC
26
Lindbrook Capital
California
$11.5K – – –
Morgan Stanley
27
Morgan Stanley
New York
$8.03K -$34.2K -9,377 -81%
UBS Group
28
UBS Group
Switzerland
$6.54K +$1.58K +435 +33%
Osaic Holdings
29
Osaic Holdings
Arizona
$2K – – –
JP Morgan Chase
30
JP Morgan Chase
New York
$1K -$3.51K -962 -73%
Wells Fargo
31
Wells Fargo
California
$263 +$15 +4 +6%
Citigroup
32
Citigroup
New York
$240 -$1.02K -281 -81%
Bank of America
33
Bank of America
North Carolina
$124 -$638 -175 -84%
NC
34
NewSquare Capital
Pennsylvania
$75 +$73 +20 New
CS
35
Credit Suisse
Switzerland
$8 – – –
OM
36
Opaleye Management
Massachusetts
– -$1.24M -255,250 Closed
Millennium Management
37
Millennium Management
New York
– -$155K -31,842 Closed
E
38
Ergoteles
New York
– -$119K -24,447 Closed
Goldman Sachs
39
Goldman Sachs
New York
– -$55K -11,220 Closed
TRCT
40
Tower Research Capital (TRC)
New York
– -$50K -10,245 Closed
BNP Paribas Financial Markets
41
BNP Paribas Financial Markets
France
– -$6.67K -1,369 Closed
CUAMC
42
China Universal Asset Management Company
China
– -$1K -223 Closed
1
2

IMPL Hedge Fund Activity: Q4 2022 in Review

35 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Impel Pharmaceuticals Inc. Common Stock (IMPL) for Q4 2022, worth a combined $99.6M — up 35% from $73.9M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of IMPL and 6 opened new positions — a net loss of 4 holders — while 10 trimmed existing stakes and 6 added.

The largest buyer was J. Goldman & Co, opening a new position worth an estimated $730K. The largest seller was Opaleye Management, exiting entirely with an estimated $1.24M sold.

  • 35 institutional investors held Impel Pharmaceuticals Inc. Common Stock (IMPL) as of Q4 2022, down from 39 in Q3 2022.
  • Funds reported $99.6M of Impel Pharmaceuticals Inc. Common Stock stock for Q4 2022, up 35% quarter-over-quarter.
  • 6 funds opened new Impel Pharmaceuticals Inc. Common Stock positions in Q4 2022 and 10 closed out, a net change of -4 holders.
  • The largest Impel Pharmaceuticals Inc. Common Stock buyer in Q4 2022 was J. Goldman & Co, an estimated $730K added.
  • The largest Impel Pharmaceuticals Inc. Common Stock seller in Q4 2022 was Opaleye Management, an estimated $1.24M sold.

Based on aggregated 13F filings for Q4 2022.